×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ANVS – annovis bio, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ANVS
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
08:00 am
anvs
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
Medium
Report
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
11/24
08:00 am
anvs
Annovis Announces Two Presentations at the CTAD 2025 Conference
High
Report
Annovis Announces Two Presentations at the CTAD 2025 Conference
11/18
08:00 am
anvs
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
High
Report
Annovis Announces FDA Meeting to Discuss Parkinson's Disease Dementia Program; Reaffirms FDA Alignment on Pivotal Phase 3 Alzheimer's Disease Study
11/17
08:00 am
anvs
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
High
Report
Annovis Reports New Biomarker Data Linking Amyloid Co-Pathology to Accelerated Cognitive Decline in Parkinson's Patients
11/12
08:00 am
anvs
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
High
Report
Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results
11/6
08:00 am
anvs
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
Medium
Report
Annovis Achieves Significant Milestones and Sustains Strong Progress in Phase 3 Alzheimer’s Program
10/27
08:00 am
anvs
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
High
Report
Annovis Announces $3.4 Million Registered Direct Offering of Common Stock Priced At-the-Market under the NYSE Rules
10/15
05:15 pm
anvs
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
High
Report
Annovis Announces Closing of $6 Million Registered Direct Offering of Common Stock
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/25
07:00 pm
anvs
Form 4/A Annovis Bio, Inc. For: Nov 24 Filed by: Hoffman Michael B
Low
Report
Form 4/A Annovis Bio, Inc. For: Nov 24 Filed by: Hoffman Michael B
11/25
12:27 pm
anvs
Form 4 Annovis Bio, Inc. For: Nov 24 Filed by: Hoffman Michael B
Medium
Report
Form 4 Annovis Bio, Inc. For: Nov 24 Filed by: Hoffman Michael B
11/21
07:58 pm
anvs
Form 4 Annovis Bio, Inc. For: Nov 21 Filed by: Hoffman Michael B
Medium
Report
Form 4 Annovis Bio, Inc. For: Nov 21 Filed by: Hoffman Michael B
11/18
07:44 am
anvs
Form 4 Annovis Bio, Inc. For: Nov 14 Filed by: Hoffman Michael B
High
Report
Form 4 Annovis Bio, Inc. For: Nov 14 Filed by: Hoffman Michael B
11/13
06:01 am
anvs
Form 8-K Annovis Bio, Inc. For: Nov 12
Medium
Report
Form 8-K Annovis Bio, Inc. For: Nov 12
11/12
04:18 pm
anvs
Form 10-Q Annovis Bio, Inc. For: Sep 30
Medium
Report
Form 10-Q Annovis Bio, Inc. For: Sep 30
11/12
09:19 am
anvs
Form 4 Annovis Bio, Inc. For: Oct 28 Filed by: Maccecchini Maria-Luisa
Medium
Report
Form 4 Annovis Bio, Inc. For: Oct 28 Filed by: Maccecchini Maria-Luisa
11/12
09:18 am
anvs
Form 4 Annovis Bio, Inc. For: Oct 28 Filed by: Hoffman Michael B
High
Report
Form 4 Annovis Bio, Inc. For: Oct 28 Filed by: Hoffman Michael B
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/28
Annovis Bio Announces Pricing of Initial Public Offering
44.6%
4/3 Form 8-K Annovis Bio, Inc. For: Apr 03 15.0%
2/13 Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease 10.5%
4/13 Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14 5.8%
4/30 Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients 5.3%
1/31 Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.4%
3/25 Form 10-K Annovis Bio, Inc. For: Dec 31 2.3%
4/20 Form SC 13D Annovis Bio, Inc. Filed by: Maccecchini Maria-Luisa 1.3%
4/23 Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies 0.3%
4/3 Form 8-K Annovis Bio, Inc. For: Apr 03 15.0%
2/13 Annovis Bio Announces Update on Phase II Clinical Trial for Alzheimer’s Disease 10.5%
4/13 Annovis Bio to Hold Investor Webinar and Q&A Session with CEO on April 14 5.8%
4/30 Annovis Bio Announces Plans for a New Phase II Clinical Trial to Treat 68 Parkinson’s and Alzheimer’s Patients 5.3%
1/31 Annovis Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 3.4%
3/25 Form 10-K Annovis Bio, Inc. For: Dec 31 2.3%
4/20 Form SC 13D Annovis Bio, Inc. Filed by: Maccecchini Maria-Luisa 1.3%
4/23 Annovis Bio Publishes Results of Alzheimer’s and Parkinson’s Animal Studies 0.3%
TOP News Decliners
1/30
Form 424B4 Annovis Bio, Inc.
-26.7%
2/14 Form S-8 Annovis Bio, Inc. -10.3%
2/6 Form 8-K Annovis Bio, Inc. For: Jan 30 -9.3%
3/19 Annovis Bio to Present at the Online Spring Investor Summit on March 25 -7.0%
5/1 Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report -3.9%
2/20 Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases -3.2%
2/5 Form 4 Annovis Bio, Inc. For: Jan 31 Filed by: Bruck Claudine -2.9%
4/15 Annovis up 23% after webinar on neurodegeneration candidates [Seeking Alpha] -2.6%
2/27 Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies -0.4%
2/14 Form S-8 Annovis Bio, Inc. -10.3%
2/6 Form 8-K Annovis Bio, Inc. For: Jan 30 -9.3%
3/19 Annovis Bio to Present at the Online Spring Investor Summit on March 25 -7.0%
5/1 Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report -3.9%
2/20 Annovis Issued Patent for Method of Treating Parkinson’s Disease and Other Lewy Body Diseases -3.2%
2/5 Form 4 Annovis Bio, Inc. For: Jan 31 Filed by: Bruck Claudine -2.9%
4/15 Annovis up 23% after webinar on neurodegeneration candidates [Seeking Alpha] -2.6%
2/27 Annovis Awarded $1.7 Million NIH Grant for ANVS401 Chronic Toxicology Studies -0.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: